



# Best of 3<sup>rd</sup> ASTRO GULF 2026

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel

## AGENDA



# Best of 3<sup>rd</sup> ASTRO GULF 2026

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel

<b>UAE Time</b>	
08:00 - 08:45	<b>Registration</b>
08:45 - 09:00	<b>Welcome &amp; Introduction</b>
<b>Breast Cancer</b>	
Moderated by:  Dr. Aydah Al Awadhi &  Dr. Noora Al Hammadi &  Dr. Maryam Aslani &  Dr. Hikmat Abdel-Razeq	
09:00 - 09:10	 <b>Prof. Tamer Refaat</b> Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial: Health-Related Quality Of Life Outcomes
09:10 - 09:20	 <b>Dr. Ibrahim Abu-Gheida</b> Standard of Care Systemic Treatment with or without Stereotactic Body Radiation Therapy (SBRT) in the Management of Patients with Newly Diagnosed Extra-cranial Oligometastatic Breast Cancer (OMBC): A Prospective Randomized Study (NCT06144346)
<b>Central Nervous System</b>	
Moderated by:  Dr. Ibrahim Alotain, and  Dr. Saif Aljabab	
09:20 - 09:30	 <b>Dr. Majed Alghamdi</b> Multicenter, Phase 3 Randomized Trial of Stereotactic Radiation vs. Hippocampal Avoidance Whole Brain Radiation in Patients with 5-20 Brain Metastases: Recurrence, Salvage Therapy, and Mortality Endpoints
09:30 - 09:40	 <b>Dr. Bassem Youssef</b> Tumor Treating Fields (TTFields) After Stereotactic Radiosurgery (SRS) for Brain Metastases from Non-Small Cell Lung Cancer (NSCLC BM): Final Results of The Phase 3 METIS Trial
09:40 - 09:50	 <b>Dr. Layth Mula-Hussain</b> Efficacy of Hypofractionated Stereotactic Radiotherapy with Different Dose Fractionation Regimens Combined with Concurrent Bevacizumab in Recurrent High-Grade Gliomas: A Randomized Controlled Trial
<b>Gastrointestinal Cancers</b>	
Moderated by:  Dr. Falah Al Khatib &  Dr. Yousra Izzuddeen KN	
09:50 - 10:00	 <b>Dr. Thuraya Al-Hajri</b> Quality of Life and 5-Year Long-Term Organ Preservation in Early Rectal Adenocarcinoma Final Results from the OPERA Trial
10:00 - 10:45	<b>Opening Ceremony</b>









# Best of 3<sup>rd</sup> ASTRO GULF 2026

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel

10:45 - 11:00 **Coffee Break**


## Genitourinary Cancers

Moderated by:  Dr. Ibrahim Abu-Gheida &  Dr. Hussam Hijazi

11:00 - 11:10	 <b>Dr. Rana Irfan Mahmood</b> Primary Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
11:10 - 11:20	 <b>Dr. Chad Tang</b> 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial
11:20 - 11:30	 <b>Prof. Ugur Selek</b> Bladder Adjuvant Radiotherapy (BART): Clinical Outcomes from a Phase III Multicenter Randomized Controlled Trial
11:30 - 11:40	 <b>Dr. Ramiz Abu-Hijlih</b> Stereotactic Radiation for Systemic Therapy-Naïve Oligometastatic Kidney Cancer: Final Results of a Phase IIb Trial
11:40 - 11:50	 <b>Dr. Chad Tang</b> Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials
11:50 - 12:00	 <b>Dr. Syed Hammad Tirmazy</b> A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial)
12:00 - 12:10	 <b>Dr. Saad Alrashidi</b> Quality of Life Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
12:10 - 12:20	 <b>Dr. Ramiz Abu-Hijlih</b> Androgen Deprivation Therapy (ADT) and High Dose Definitive Radiotherapy (RT) +/- Whole Pelvic RT in Patients with Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: Early Results of a Phase III Randomized Controlled Trial












## Gynecological Cancers

Moderated by:  Dr. Yoginee Pundlik Sonawane

12:20 - 12:30	 <b>Dr. Zeinab Ibraheem</b> Impact of MMR Status vs. Clinicopathologic Risk Factors on Locoregional Recurrence in Stage I Endometrioid Endometrial Cancer Treated with Brachytherapy Alone
---------------	--

# Best of 3<sup>rd</sup> ASTRO GULF 2026

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel




12:30 - 12:40	 <b>Dr. Eter Natelauri</b> Phase 3 Study of Pembrolizumab (Pembro) + Adjuvant Chemotherapy (CT) ± Radiotherapy (RT) for Newly Diagnosed, High-Risk Endometrial Cancer (EC): Exploratory Analysis of Disease-Specific-Free Survival (DSFS) and Safety by Radiation Usage
<h2>Head and Neck Cancer</h2> <p>Moderated by:  Dr. Ibrahim Alotain &amp;  Dr. Anan Bamakhrama &amp;  Dr. Saif Aljabab</p>	
12:40 - 12:50	 <b>Dr. Mohammed Aldehaim</b> Primary Results for the Phase III Trial of Toxicity Reduction using Proton Beam Therapy for Oropharyngeal Cancer (TORPEdO; CRUK/18/010)
12:50 - 13:00	 <b>Dr. Bassem Youssef</b> A Phase IV Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) as a Standard of Care in Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma
13:00 - 13:10	 <b>Dr. Issa Mohamad</b> Neoadjuvant and Adjuvant Pembrolizumab (Pembro) Plus Standard of Care (SOC) in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC): Postoperative Risk Subgroup Analysis of KEYNOTE-689
13:10 - 14:10	<b>Lunch Break</b>
<h2>Hematologic Malignancies</h2> <p>Moderated by:  Dr. Sangeetha Ponnusamy</p>	
14:10 - 14:20	 <b>Dr. Yusra Izzuddeen KN</b> Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group
14:20 - 14:30	 <b>Dr. Taghreed Al Hindi</b> Phase II Trial of 'Re-Priming' Radiation Therapy for Relapsed/Refractory Non-Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-cell (CAR-T) Therapy
14:30 - 14:40	 <b>Dr. Ismail Ghorbel</b> Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study
14:40 - 14:50	<b>Coffee Break</b>

# Best of 3<sup>rd</sup> ASTRO GULF 2026

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel

## Lung Cancer/Thoracic Malignancies

Moderated by:  Dr. Eter Natelauri &  Dr. Faiz Alshafa

14:50 - 15:00	 <b>Dr. Ahmed Bushehri</b> Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC)
15:00 - 15:10	 <b>Prof. Ugur Selekt</b> Ten-Year Outcomes of the Revised STARS Trial Comparing Radiation and Surgery for Early-Stage Non-Small Cell Lung Cancer
15:10- 15:20	 <b>Dr. Bassem Youssef</b> Sequential Chemo-Immunotherapy plus Optimized Thoracic Radiotherapy vs. Standard Thoracic Radiotherapy for Elderly and/ or Frail Stage III Non-Small-Cell Lung Cancer: A Randomized Open-Label Controlled Trial of iLCC-3



## Benign Disease(s)

Moderated by:  Dr. Thuraya Al-Hajri &  Dr. Saif Aljabab

15:20 - 15:30	 <b>Dr. Sangeetha Ponnusamy</b> Toxicities and Quality of Life Following Observation or Radiation Therapy for Dupuytren's Disease in the International DEPART Randomized Trial
15:30 - 15:40	 <b>Dr. Ahmed Bushehri</b> Stereotactic Arrhythmia Radiotherapy (STAR) vs. Repeat Catheter Ablation for High-Risk Refractory Ventricular Tachycardia: 3-Year Safety and Efficacy Outcomes
15:40 - 15:50	 <b>Dr. Thamer Habib</b> Clinical Effectiveness of Single Course Low-Dose Radiation Therapy in Knee Osteoarthritis: Short-term Results from the Randomized, Sham-Controlled Trial


## Metastatic and Oligometastatic Disease Session

Moderated by:  Dr. Faiz Alshafa &  Dr. Issa Mohamad

15:50 - 16:00	 <b>Dr. Chad Tang</b> Addition of Metastasis-Directed Therapy to Standard of Care: Primary Aggregate Analysis and Immunologic Correlatives of the Phase II Randomized EXTEND Trial
16:00 - 16:10	 <b>Dr. Wael El-Sheshtawy</b> Treatment with Stereotactic Ablative Radiotherapy for up to Five Oligometastases in Patients with Cancer: Long-Term Outcomes of the Nonrandomized Phase 2 SABR-5 Clinical Trial

Best of  
**3<sup>rd</sup> ASTRO**  
**GULF 2026**

Saturday 31<sup>st</sup> January, 2026 | Anantara Downtown Dubai Hotel

16:10 - 16:20	 <b>Dr. Toufic Eid</b> Predictors of Skeletal-Related Events and Quality of Life Dimensions among Patients with High-Risk, Asymptomatic Bone Metastases with or without Early Radiation Therapy: Secondary Analysis of a Multicenter, Randomized Phase II Clinical Trial
16:20 - 16:30	<b>Closing Remarks</b>